valproic acid has been researched along with Agitation, Psychomotor in 54 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| ""Valproic acid", "valproate", "sodium valproate", "delirium", "acute mania with delirium" in PubMed and Ovid." | 9.22 | Valproic Acid in the Management of Delirium. ( Cuartas, CF; Davis, M, 2022) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 8.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "Valproic acid is widely used in the treatment of behavioral disturbances in patients with dementia; however, there is uncertainty about its dosing and studies have reported mixed findings." | 8.88 | Valproic acid in dementia: does an optimal dose exist? ( Dolder, CR; McKinsey, J; Nealy, KL, 2012) |
| "To determine whether evidence supports the use of valproic acid in the treatment of agitation of people with dementia." | 8.82 | Valproic acid for agitation in dementia. ( Cameron, M; Lonergan, ET; Luxenberg, J, 2004) |
| " VPA-exposed male pups were administered with two doses of ibudilast (5 and10 mg/kg) and all the groups were evaluated for behavioral parameters like social interaction, spatial memory/learning, anxiety, locomotor activity, and nociceptive threshold." | 8.31 | Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder. ( Gautam, V; Kumar, A; Rawat, K; Saha, L; Sandhu, A; Sharma, A, 2023) |
| "Valproic acid has been proposed as an alternative agent for treatment of agitation and delirium in the intensive care unit (ICU)." | 7.96 | Valproic Acid for the Management of Agitation and Delirium in the Intensive Care Setting: A Retrospective Analysis. ( Crowley, KE; Geiger, KL; Hacobian, G; Urben, L, 2020) |
| "Valproic acid, an anticonvulsant medication that enhances GABAergic neurotransmission, has been shown to be helpful in treating behavioural disturbances associated with dementia in several small case series." | 7.70 | Valproic acid treatment of agitation in dementia. ( Herrmann, N, 1998) |
| "Valproic acid (VPA) is a potential pharmacologic agent that can be utilized to treat ICU delirium, though there is a paucity of evidence for its use, especially in patients with a history of substance abuse." | 6.72 | Prolonged Refractory ICU Delirium Successfully Treated With Valproic Acid: Case Report and Literature Review. ( Louzon, PR; Masood, A; Recksieck, S; Subedi, B, 2021) |
| "Topiramate is an antiepileptic drug, recently also used in the treatment of psychiatric diseases." | 5.33 | Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. ( Gaudreau, PO; Gobbi, G; Leblanc, N, 2006) |
| ""Valproic acid", "valproate", "sodium valproate", "delirium", "acute mania with delirium" in PubMed and Ovid." | 5.22 | Valproic Acid in the Management of Delirium. ( Cuartas, CF; Davis, M, 2022) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 4.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "Valproic acid is widely used in the treatment of behavioral disturbances in patients with dementia; however, there is uncertainty about its dosing and studies have reported mixed findings." | 4.88 | Valproic acid in dementia: does an optimal dose exist? ( Dolder, CR; McKinsey, J; Nealy, KL, 2012) |
| " The purpose of this review of the literature is to assess the interest and the limits of anticonvulsant mood stabilizers (carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate, oxcarbazepine) in the treatment of the so-called "noncognitive" symptoms of dementia." | 4.84 | [Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)]. ( Pinheiro, D, 2008) |
| "To determine whether evidence supports the use of valproic acid in the treatment of agitation of people with dementia." | 4.82 | Valproic acid for agitation in dementia. ( Cameron, M; Lonergan, ET; Luxenberg, J, 2004) |
| " VPA-exposed male pups were administered with two doses of ibudilast (5 and10 mg/kg) and all the groups were evaluated for behavioral parameters like social interaction, spatial memory/learning, anxiety, locomotor activity, and nociceptive threshold." | 4.31 | Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder. ( Gautam, V; Kumar, A; Rawat, K; Saha, L; Sandhu, A; Sharma, A, 2023) |
| "Valproic acid has been proposed as an alternative agent for treatment of agitation and delirium in the intensive care unit (ICU)." | 3.96 | Valproic Acid for the Management of Agitation and Delirium in the Intensive Care Setting: A Retrospective Analysis. ( Crowley, KE; Geiger, KL; Hacobian, G; Urben, L, 2020) |
| " Lower doses of valproate and carbamazepine were required to prevent hyperactivity compared to doses required to block tonic-clonic seizures induced by pentylenetetrazole." | 3.73 | Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. ( Arban, R; Brackenborough, K; Gerrard, P; Large, C; Maraia, G; Wilson, A; Winyard, L, 2005) |
| "Valproic acid, an anticonvulsant medication that enhances GABAergic neurotransmission, has been shown to be helpful in treating behavioural disturbances associated with dementia in several small case series." | 3.70 | Valproic acid treatment of agitation in dementia. ( Herrmann, N, 1998) |
| " For 80 patients treated with sodium valproate, the mean ± SD dosage was 1541." | 2.80 | Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. ( Asadollahi, S; Azadbakht, A; Hatamabadi, H; Heidari, K; Mirmohseni, L; Vafaee, R; Yunesian, S, 2015) |
| "Agitation and psychosis are common in Alzheimer disease and cause considerable morbidity." | 2.76 | Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. ( Aisen, PS; Bartocci, B; Cummings, J; Fleisher, A; Ismail, MS; Jack, CR; Jakimovich, LJ; Loy, R; Porsteinsson, A; Raman, R; Schneider, LS; Tariot, PN; Thal, L; Thomas, RG; Weiner, M, 2011) |
| "The goal of this study was to determine if manifestations of agitation (ie, physical aggression, physically nonaggressive behavior, and verbally agitated behaviors) show different degrees of response to divalproex sodium (extended release or sprinkles) alone or in combination with second-generation antipsychotic agents." | 2.73 | Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication. ( Adkison, L; Ahokpossi, C; Forester, B; Hyde, J; Perez, R; Sribney, W; Vanelli, M, 2007) |
| "Valproic acid (VPA) is a potential pharmacologic agent that can be utilized to treat ICU delirium, though there is a paucity of evidence for its use, especially in patients with a history of substance abuse." | 2.72 | Prolonged Refractory ICU Delirium Successfully Treated With Valproic Acid: Case Report and Literature Review. ( Louzon, PR; Masood, A; Recksieck, S; Subedi, B, 2021) |
| "Valproic acid derivatives have been used for the past 10 years to control agitation in dementia, but no systematic review of the effectiveness of this treatment has been published to date." | 2.45 | Valproate preparations for agitation in dementia. ( Lonergan, E; Luxenberg, J, 2009) |
| "Valproic acid is an alternative treatment option." | 1.62 | Prescribing Practices of Valproic Acid for Agitation and Delirium in the Intensive Care Unit. ( Duggal, A; Hohlfelder, B; Quinn, NJ; Torbic, H; Wanek, MR, 2021) |
| "The 6-Hz-induced seizures were accompanied by reduced brain 5-HT, DA, NE, histamine, GABA, and enhanced glutamate levels." | 1.46 | Parachlorophenylalanine-induced 5-HT depletion alters behavioral and brain neurotransmitters levels in 6-Hz psychomotor seizure model in mice. ( Jahan, K; Pillai, KK; Vohora, D, 2017) |
| "Akathisia is a syndrome characterized by the unpleasant sensation of "inner" restlessness that manifests itself in the inability of sitting still or not moving." | 1.37 | Symptoms of agitated depression and/or akathisia. ( Blažević-Zelić, S; Peitl, MV; Peitl, V; Prološčić, J; Skarpa-Usmiani, I, 2011) |
| "Topiramate is an antiepileptic drug, recently also used in the treatment of psychiatric diseases." | 1.33 | Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. ( Gaudreau, PO; Gobbi, G; Leblanc, N, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.85) | 18.7374 |
| 1990's | 8 (14.81) | 18.2507 |
| 2000's | 24 (44.44) | 29.6817 |
| 2010's | 14 (25.93) | 24.3611 |
| 2020's | 7 (12.96) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, A | 1 |
| Sharoha, N | 1 |
| Sandhu, A | 1 |
| Rawat, K | 1 |
| Gautam, V | 1 |
| Sharma, A | 1 |
| Kumar, A | 1 |
| Saha, L | 1 |
| Crowley, KE | 1 |
| Urben, L | 1 |
| Hacobian, G | 1 |
| Geiger, KL | 1 |
| Quinn, NJ | 1 |
| Hohlfelder, B | 1 |
| Wanek, MR | 1 |
| Duggal, A | 1 |
| Torbic, H | 1 |
| Subedi, B | 1 |
| Louzon, PR | 1 |
| Masood, A | 1 |
| Recksieck, S | 1 |
| Kang, Q | 1 |
| Yang, L | 1 |
| Liao, H | 1 |
| Wu, L | 1 |
| Chen, B | 1 |
| Yang, S | 1 |
| Kuang, X | 1 |
| Yang, H | 1 |
| Liao, C | 1 |
| Cuartas, CF | 1 |
| Davis, M | 1 |
| Ostinelli, EG | 1 |
| Hussein, M | 1 |
| Ahmed, U | 1 |
| Rehman, FU | 1 |
| Miramontes, K | 1 |
| Adams, CE | 1 |
| Baillon, SF | 1 |
| Narayana, U | 1 |
| Luxenberg, JS | 1 |
| Clifton, AV | 1 |
| Connolly, S | 1 |
| Caldwell, SB | 1 |
| Wilson, FC | 1 |
| Asadollahi, S | 1 |
| Heidari, K | 1 |
| Hatamabadi, H | 1 |
| Vafaee, R | 1 |
| Yunesian, S | 1 |
| Azadbakht, A | 1 |
| Mirmohseni, L | 1 |
| Kasper, S | 1 |
| Gagnon, DJ | 1 |
| Fontaine, GV | 1 |
| Smith, KE | 1 |
| Riker, RR | 1 |
| Miller, RR | 1 |
| Lerwick, PA | 1 |
| Lucas, FL | 1 |
| Dziodzio, JT | 1 |
| Sihler, KC | 1 |
| Fraser, GL | 1 |
| Jahan, K | 1 |
| Pillai, KK | 1 |
| Vohora, D | 1 |
| Pinheiro, D | 1 |
| Lonergan, E | 1 |
| Luxenberg, J | 2 |
| Flanagan, SR | 1 |
| Elovic, EP | 1 |
| Sandel, E | 1 |
| Dolder, C | 1 |
| McKinsey, J | 2 |
| Belaizi, M | 1 |
| Mehssani, J | 1 |
| Yahyaoui, M | 1 |
| Fajri, A | 1 |
| Mizukami, K | 1 |
| Hatanaka, K | 1 |
| Ishii, T | 1 |
| Iwakiri, M | 1 |
| Sodeyama, N | 1 |
| Tanaka, Y | 1 |
| Asada, T | 1 |
| Peitl, MV | 1 |
| Prološčić, J | 1 |
| Blažević-Zelić, S | 1 |
| Skarpa-Usmiani, I | 1 |
| Peitl, V | 1 |
| Tariot, PN | 4 |
| Schneider, LS | 1 |
| Cummings, J | 1 |
| Thomas, RG | 1 |
| Raman, R | 2 |
| Jakimovich, LJ | 1 |
| Loy, R | 2 |
| Bartocci, B | 1 |
| Fleisher, A | 1 |
| Ismail, MS | 1 |
| Porsteinsson, A | 3 |
| Weiner, M | 1 |
| Jack, CR | 1 |
| Thal, L | 2 |
| Aisen, PS | 1 |
| Dolder, CR | 1 |
| Nealy, KL | 1 |
| Hung, WC | 1 |
| Hsieh, MH | 1 |
| Pratt, CE | 1 |
| Davis, SM | 1 |
| Olson, DA | 1 |
| Ingram, W | 1 |
| Mann, JR | 1 |
| Ryan, JM | 1 |
| Ismail, S | 1 |
| Alderfer, BS | 1 |
| Allen, MH | 1 |
| Vance, H | 1 |
| Kauffman, C | 1 |
| Miller, B | 1 |
| Mansour, T | 1 |
| Lonergan, ET | 1 |
| Cameron, M | 1 |
| Cummings, MR | 1 |
| Miller, BD | 1 |
| Arban, R | 1 |
| Maraia, G | 1 |
| Brackenborough, K | 1 |
| Winyard, L | 1 |
| Wilson, A | 1 |
| Gerrard, P | 1 |
| Large, C | 1 |
| Bourgeois, JA | 1 |
| Koike, AK | 1 |
| Simmons, JE | 1 |
| Telles, S | 1 |
| Eggleston, C | 1 |
| Debattista, C | 2 |
| Solomon, A | 1 |
| Arnow, B | 1 |
| Kendrick, E | 1 |
| Tilston, J | 1 |
| Schatzberg, AF | 2 |
| Jakimovich, L | 2 |
| Schneider, L | 1 |
| Thomas, R | 1 |
| Mintzer, J | 1 |
| Brenner, R | 1 |
| Schafer, K | 1 |
| Kratochvil, CJ | 1 |
| Varley, C | 1 |
| Cummins, TK | 1 |
| Martin, A | 1 |
| Gobbi, G | 1 |
| Gaudreau, PO | 1 |
| Leblanc, N | 1 |
| Herrmann, N | 2 |
| Lanctôt, KL | 1 |
| Rothenburg, LS | 1 |
| Eryavec, G | 1 |
| Siniscalchi, A | 1 |
| Gallelli, L | 1 |
| De Fazio, S | 1 |
| De Sarro, G | 1 |
| Yoshimura, R | 1 |
| Shinkai, K | 1 |
| Ueda, N | 1 |
| Nakamura, J | 1 |
| Buckley, PF | 1 |
| Paulsson, B | 1 |
| Brecher, M | 1 |
| Forester, B | 1 |
| Vanelli, M | 1 |
| Hyde, J | 1 |
| Perez, R | 1 |
| Ahokpossi, C | 1 |
| Sribney, W | 1 |
| Adkison, L | 1 |
| Boeckh, E | 1 |
| Lott, AD | 1 |
| McElroy, SL | 1 |
| Keys, MA | 1 |
| Horne, M | 1 |
| Lindley, SE | 1 |
| Wilcox, J | 1 |
| Zayas, EM | 1 |
| Grossberg, GT | 1 |
| Kunik, ME | 1 |
| Puryear, L | 1 |
| Orengo, CA | 1 |
| Molinari, V | 1 |
| Workman, RH | 1 |
| Hilty, DM | 1 |
| Rodriguez, GD | 1 |
| Hales, RE | 1 |
| Norton, JW | 1 |
| Quarles, E | 1 |
| Chatham Showalter, PE | 1 |
| Kimmel, DN | 1 |
| Porsteinsson, AP | 1 |
| Erb, R | 1 |
| Cox, C | 1 |
| Smith, E | 1 |
| Noviasky, J | 1 |
| Kowalski, N | 1 |
| Holt, CJ | 1 |
| Irvine, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)[NCT00071721] | Phase 3 | 313 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver rating questionnaire for the assessment of agitation in older persons. It includes descriptions of 29 agitated behaviors, each rated on a 7-point scale of frequency. The range of this instrument is 29 to 203 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 10.6 |
| Placebo | 12.1 |
Alzheimer's Disease Assessment Scale, cognitive sub-scale in points per year (ADAS-cog) is a psychometric measure sensitive to change in mild to moderate AD. The range of this instrument is 0 to 70 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 42.3 |
| Placebo | 41.9 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Score (ADCS-ADL) is a structured questionnaire about activities of daily living, administered to the subject's caregiver/study partner. The range of this instrument is 0 to 78 with lower numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 35.1 |
| Placebo | 41.0 |
Clinical Dementia Rating, Sum of Boxes (CDR-SOB) is a global rating of dementia severity based on the clinician's interpretation of the history and examination. The range of this instrument is 0 to 18 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 12.0 |
| Placebo | 11.5 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) provides a means to reliably assess global change from baseline. It provides a semi-structured format to allow clinicians to gather necessary clinical information from both the participant and informant, in order to make an overall impression of clinical change. The range of this instrument is 1 to 7 with lower numbers indicating improvement and higher numbers indicating a worsened state. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 5.7 |
| Placebo | 5.5 |
NPI quantifies behavioral changes in dementia, including depression, anxiety, psychosis, agitation, and others. This is a questionnaire administered to the subject's study partner. The range of this instrument is 0 to 120 with higher numbers indicating greater impairment. To determine whether or not psychosis or agitation is present, there is no cutoff score but is based on the clinician's judgment. In the NPI, the subject responds to 'Yes' or 'No' questions. Then it is determined how often psychosis or agitation occurs and if it is mild, moderate or severe. (NCT00071721)
Timeframe: 24 months
| Intervention | Participants (Number) |
|---|---|
| Valproate | 25 |
| Placebo | 29 |
14 reviews available for valproic acid and Agitation, Psychomotor
| Article | Year |
|---|---|
Prolonged Refractory ICU Delirium Successfully Treated With Valproic Acid: Case Report and Literature Review.
Topics: Adult; Antipsychotic Agents; Delirium; Female; Humans; Intensive Care Units; Psychomotor Agitation; | 2021 |
Valproic Acid in the Management of Delirium.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Humans; Male; Middle Aged; Psychomotor Agita | 2022 |
Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Carbamazepine; Humans; Oxcarbazepine; Psycho | 2018 |
Valproate preparations for agitation in dementia.
Topics: Aged; Aggression; Antimanic Agents; Cognition; Dementia; Humans; Psychomotor Agitation; Randomized C | 2018 |
[Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)].
Topics: Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dementia; Fructose; Gabap | 2008 |
Valproate preparations for agitation in dementia.
Topics: Aged; Antimanic Agents; Dementia; Humans; Psychomotor Agitation; Randomized Controlled Trials as Top | 2009 |
Valproic acid in dementia: does an optimal dose exist?
Topics: Dementia; Dose-Response Relationship, Drug; Humans; Psychomotor Agitation; Psychotropic Drugs; Rando | 2012 |
Divalproex sodium therapy in elderly with dementia-related agitation.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Clinical Trials as Topic; Dementia; Humans; Psychomotor A | 2002 |
Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Mood Disorders; Neuroprotective Agents | 2002 |
Treatment of agitation in bipolar disorder across the life cycle.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Age of Onset; Anticonvulsants; Antipsychotic Agents; | 2003 |
Valproic acid for agitation in dementia.
Topics: Aged; Antimanic Agents; Dementia; Humans; Psychomotor Agitation; Randomized Controlled Trials as Top | 2004 |
Pharmacologic management of behavioral instability in medically ill pediatric patients.
Topics: Adolescent; Adrenergic alpha-Agonists; Aggression; Analgesics, Non-Narcotic; Behavior Therapy; Behav | 2004 |
Phenomenology and treatment of agitation.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 1999 |
Intravenous valproate in neuropsychiatry.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Clinical Trials | 2000 |
11 trials available for valproic acid and Agitation, Psychomotor
| Article | Year |
|---|---|
Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; | 2015 |
Low-dose divalproex in agitated patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antimanic Agents; Female; Humans; Male; Psychomotor Agit | 2010 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
The efficacy of divalproex sodium in the treatment of agitation associated with major depression.
Topics: Adult; Aged; Antimanic Agents; Anxiety; Depression; Depressive Disorder, Major; Female; Humans; Male | 2005 |
Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dose-Response Relationship, Drug; Double-Blind Method; D | 2005 |
A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anticonvulsants; Cognition Disorders; Double | 2007 |
Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
Topics: Aged; Aged, 80 and over; Aggression; Antimanic Agents; Antipsychotic Agents; Behavioral Symptoms; De | 2007 |
Valproate in the treatment of behavioral agitation in elderly patients with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Female; Humans; Male; Prospective Studies; | 1995 |
Divalproex sodium in the treatment of aggressive behavior.
Topics: Adult; Aggression; Bipolar Disorder; Borderline Personality Disorder; Case-Control Studies; Female; | 1994 |
The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Drug Tolerance; Female; GABA Agents; Humans | 1998 |
Placebo-controlled study of divalproex sodium for agitation in dementia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antimanic Agents; Dementia; Dose-Response Relationshi | 2001 |
29 other studies available for valproic acid and Agitation, Psychomotor
| Article | Year |
|---|---|
Valproate Efficacy for Agitation Management in a Patient With Paroxysmal Sympathetic Hyperactivity Due to Traumatic Brain Injury.
Topics: Brain Injuries, Traumatic; Humans; Psychomotor Agitation; Valproic Acid | 2021 |
Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder.
Topics: Animals; Anxiety; Autism Spectrum Disorder; Disease Models, Animal; Female; Inflammation Mediators; | 2023 |
Valproic Acid for the Management of Agitation and Delirium in the Intensive Care Setting: A Retrospective Analysis.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antipsychotic Agents; Benzodiazepines; Critical Care; C | 2020 |
Prescribing Practices of Valproic Acid for Agitation and Delirium in the Intensive Care Unit.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Cohort Studies; Female; Humans; Incidence; Intensive Ca | 2021 |
CNKSR2 gene mutation leads to Houge type of X-linked syndromic mental retardation: A case report and review of literature.
Topics: Adaptor Proteins, Signal Transducing; Anticonvulsants; Child; Codon, Nonsense; Epilepsy; Humans; Int | 2021 |
Maintaining community living with post brain injury agitation: a role for sodium valproate.
Topics: Adult; Aggression; Antipsychotic Agents; Aphasia; Brain Injuries; Community Integration; Humans; Mal | 2013 |
Editorial.
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; Psych | 2016 |
Valproate for agitation in critically ill patients: A retrospective study.
Topics: Adult; Aged; Analgesics, Opioid; Critical Illness; Delirium; Dexmedetomidine; Female; Fentanyl; GABA | 2017 |
Parachlorophenylalanine-induced 5-HT depletion alters behavioral and brain neurotransmitters levels in 6-Hz psychomotor seizure model in mice.
Topics: Animals; Brain; Disease Models, Animal; Electroshock; gamma-Aminobutyric Acid; Glutamine; Male; Mice | 2017 |
Managing agitation associated with traumatic brain injury: behavioral versus pharmacologic interventions?
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Behavior Control; Brain Injuries; Dibenzothiazepines; | 2009 |
[Psychotic disorder revealing epilepsy linked to a dysembryoma of the left hippocampus].
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Diagnosis, Differential; Electroencepha | 2011 |
Effects of sodium valproate on behavioral disturbances in elderly outpatients with dementia.
Topics: Aged; Aged, 80 and over; Aggression; Antimanic Agents; Dementia; Dose-Response Relationship, Drug; F | 2010 |
Symptoms of agitated depression and/or akathisia.
Topics: Affective Disorders, Psychotic; Akathisia, Drug-Induced; Anticonvulsants; Antidepressive Agents, Sec | 2011 |
Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients.
Topics: Aged, 80 and over; Antimanic Agents; Antipsychotic Agents; Asian People; Bipolar Disorder; Dementia, | 2012 |
Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; H | 2002 |
Treatment of agitation using Depakote: a patient with dementia.
Topics: Affect; Aggression; Alzheimer Disease; Anxiety; Cooperative Behavior; Dose-Response Relationship, Dr | 2003 |
Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Bipolar Disorder; Carbamazepine; Central Nervous Syst | 2005 |
Adjunctive valproic acid for delirium and/or agitation on a consultation-liaison service: a report of six cases.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Delirium; Fever; Humans; Injections, Intra | 2005 |
Less is more: inpatient management of a child with complex pharmacotherapy.
Topics: Aggression; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Depressio | 2006 |
Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Case-Control Studies; Dr | 2006 |
Psychic disturbances associated with sodium valproate plus levetiracetam.
Topics: Anticonvulsants; Anxiety; Drug Therapy, Combination; Epilepsies, Partial; Female; Humans; Levetirace | 2007 |
Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Drug Interactions; Female; Homovanillic Acid; Humans; | 2007 |
Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
Topics: Adult; Aggression; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinical Trials, Phase | 2007 |
[The alcohol withdrawal syndrome and its therapy].
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Humans; Middle Aged; Patient Compliance; Psychomotor | 1980 |
Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes.
Topics: Adult; Aged; Aged, 80 and over; Aggression; Anger; Depression; Humans; Middle Aged; Neurocognitive D | 1995 |
Treating the agitated Alzheimer patient.
Topics: Adrenergic beta-Antagonists; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Buspirone; C | 1996 |
Valproic acid treatment of agitation in dementia.
Topics: Aged; Aged, 80 and over; Dementia; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1998 |
Intravenous valproate for rapid stabilization of agitation in neuropsychiatric disorders.
Topics: Aggression; Anticonvulsants; Autistic Disorder; Child; Female; Humans; Infusions, Intravenous; Psych | 1998 |
Agitated symptom response to divalproex following acute brain injury.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antimanic Agents; Brain Injuries; Cohort | 2000 |